Quantcast

Latest Vanda Pharmaceuticals Inc. Stories

2011-08-04 06:00:00

ROCKVILLE, Md., Aug. 4, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the second quarter and six months ended June 30, 2011. "We are pleased with our progress towards our vision of building a CNS specialty pharmaceutical company. Fanapt® scripts in the U.S....

2011-08-01 06:00:00

ROCKVILLE, Md., August 1, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced its exclusive license agreement with Argentina-based Biotoscana Farma S.A., a wholly owned affiliate of Biotoscana International, based in Bogota, Colombia, for the commercialization of Fanapt (TM) in Argentina. "We are very excited to achieve this...

2011-07-26 06:00:00

ROCKVILLE, Md., July 26, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announced today that the European Medicines Agency (EMA) accepted for evaluation Vanda's Marketing Authorization Application (MAA) for oral iloperidone tablets. Iloperidone is an atypical antipsychotic for the treatment of schizophrenia in adults. "The submission in the European Union is an important milestone towards advancing the iloperidone franchise," said Mihael H. Polymeropoulos, M.D., Vanda's...

2011-07-20 14:00:00

ROCKVILLE, Md., July 20, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced it will release results for the second quarter of 2011, on Thursday, August 4, 2011, before the market opens. A full text copy of the release will be disseminated at that time. Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer, will...

2011-07-11 06:00:00

ROCKVILLE, Md., July 11, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced its exclusive license agreement with Probiomed S.A. de C.V., a wholly owned pharmaceutical operating unit of Proquifin S.A. de C.V., for the commercialization of Fanapt(TM) in Mexico. "We are very excited to achieve this step on the path towards making...

2011-07-08 07:00:00

ROCKVILLE, Md., July 8, 2011 /PRNewswire/ -- For most people, the clock changes just twice a year for Daylight Saving Time. But for someone with Non-24-Hour Sleep-Wake Disorder (N24HWD, or Non-24), their internal body clock changes every day. In the U.S. alone, it is estimated that approximately 65,000 - 95,000 people suffer from Non-24, a sleep disorder in which a person's sleep period can advance by about 15 minutes each night. Patients suffering from Non-24 experience severe insomnia...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related